|
|
|
|
IRVINE--- Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed On
Spectrum Pharmaceuticals, Inc.(NASDAQ:SPPI) and Cell Therapeutics, Inc. (NASDAQ:CTIC)(MTA: CTIC) announced today they have entered into an agreement to form a 50/50 owned joint venture, RIT Oncology LLC, to commercialize and develop...
|
|
|
Ovarian Cancer Subtypes Are Different Diseases: Implications For Biomarker Studies
In a new analysis of tissue biomarkers expressed in ovarian cancer samples, David Huntsman and his colleagues from Vancouver General Hospital suggest that substantial differences exist between ovarian cancer subtypes which should be...
|
|
|
Ovarian Cancer Subtypes Are Different Diseases: Implications For Biomarker Studies
ScienceDaily (Dec.1, 2008) In a new analysis of tissue biomarkers expressed in ovarian cancer samples David Huntsman and his colleagues from Vancouver General Hospital suggest that substantial differences exist between ovarian cancer...
|
|
|
Ovarian cancer subtypes are different diseases: Implications for biomarker studies
In a new analysis of tissue biomarkers expressed in ovarian cancer samples, published by PLoS Medicine, David Huntsman and his colleagues from Vancouver General Hospital suggest that substantial differences exist between ovarian cancer...
|
|
|
Coronary CTA is a low cost, non-invasive alternative for evaluating coronary artery disease
Coronary CTA offers a low cost, non-invasive alternative to conventional angiography for evaluating patients who are suspected of having coronary artery disease; true even if the patients have calcified coronary artery plaques,...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
- Spectrum Pharmaceuticals, Inc.(NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC)(MTA:CTIC), received notice that the U.S. Food and Drug Administration (FDA) has...
|
|
|
IRVINE--- Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed On
Spectrum Pharmaceuticals, Inc.(NASDAQ:SPPI) and Cell Therapeutics, Inc. (NASDAQ:CTIC)(MTA: CTIC) announced today they have entered into an agreement to form a 50/50 owned joint venture, RIT Oncology LLC, to commercialize and develop...
|
|
|
IRVINE--- Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision
Spectrum Pharmaceuticals, Inc.(NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC)(MTA:CTIC), received notice that the U.S. Food and Drug Administration (FDA) has...
|
|
|
Spectrum Pharmaceuticals, Inc. (SPPI) Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decisi
IRVINE, Calif.--(BUSINESS WIRE)-- (NasdaqGM:SPPI - News) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc.(CTI) (NASDAQ:CTIC - News)(MTA:CTIC), received notice that the U.S. Food and Drug Administration...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc.(NasdaqGM:SPPI - News) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC - News)(MTA:CTIC), received notice that the U.S...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
Spectrum Pharmaceuticals, Inc.(NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC)(MTA:CTIC), received notice that the U.S. Food and Drug Administration (FDA) has...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
News source: Business Wire Spectrum Pharmaceuticals, Inc.(NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC)(MTA:CTIC), received notice that the U.S. Food and Drug...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
Spectrum Pharmaceuticals, Inc.(NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC)(MTA:CTIC), received notice that the U.S. Food and Drug Administration (FDA) has...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target
Spectrum Pharmaceuticals, Inc.(NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC)(MTA:CTIC), received notice that the U.S. Food and Drug Administration (FDA) has...
|
|
|
Spectrum Pharmaceuticals Announces Zevalin sBLA Granted Priority Review by the FDA
Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.This does not represent any evaluation of the adequacy of the data submitted. A Prescription Drug User Fee Act (PDUFA) target date of...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
American Society of Hematology conference IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc.(NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC)(MTA:CTIC),...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
IRVINE, Calif.- (Business Wire) Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC)(MTA:CTIC), received notice that the U.S. Food and...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
Pharmaceuticals, Inc.(NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC)(MTA:CTIC), received notice that the U.S. Food and Drug Administration (FDA) has accepted for...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority
Spectrum Pharmaceuticals, Inc.SPPI today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) CTIC(MTA:CTIC), received notice that the U.S. Food and Drug Administration (FDA) has accepted for filing and...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc.(NasdaqGM:SPPI - News) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ:CTIC - News)(MTA:CTIC), received notice that the U.S...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
IRVINE, Calif.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc.(NasdaqGM: SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (NASDAQ: CTIC)(MTA: CTIC), received notice that the U.S. Food...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
(BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc.(NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN, Cell Therapeutics, Inc. (CTI) (CTIC: CTIC News, chart, profile, more Last: Delayed quote data Add to portfolio...
|
|
|
Spectrum Pharmaceuticals Announces ZEVALIN sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
Also News Release (U-CTIC) CELL THERAPEUTICS INC Company Website: http:www.spectrumpharm.com IRVINE, Calif.-- (Business Wire) Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI) today announced that its joint venture partner for ZEVALIN,...
|
|
|
Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Dru
IRVINE, Calif., and SEATTLE, Nov.26 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) and Cell Therapeutics, Inc. (Nasdaq: CTIC)(MTA: CTIC) announced today they have entered into an agreement to form a 50/50...
|
|
|
Spectrum, CTI to jointly market Zevalin in US
Spectrum Pharmaceuticals, Inc.and Cell Therapeutics, Inc. (CTI) have entered into an agreement to form a 50/50 owned joint venture, RIT Oncology LLC, to commercialize and develop Zevalin ([90Y]-ibritumomab tiuxetan) in the United States...
|
